Myriad Genetics, Inc. reported a total revenue of $824.5 million for the fiscal year ending December 31, 2025, reflecting a 2% decrease from the previous year's revenue of $837.6 million. The company experienced a net loss of $365.9 million, compared to a loss of $127.3 million in 2024. This significant increase in losses was primarily attributed to a goodwill impairment charge of $234.7 million and additional long-lived asset impairments totaling $82 million. The average revenue per test also declined, particularly in the Mental Health segment, which saw a 15% drop due to changes in coverage policies by UnitedHealthcare affecting the GeneSight test.
In terms of operational metrics, Myriad Genetics reported a slight increase in total testing volumes, which rose by 1% year-over-year to 1.54 million tests. The Hereditary Cancer segment saw a 7% increase in volume, while the Mental Health segment experienced a 6% increase despite the revenue decline. The company has been focusing on expanding its product offerings, including the MyRisk Hereditary Cancer Test, which now includes 63 genes across 11 cancer types, and the FirstGene Multiple Prenatal Screen, which is currently in early access trials.
Strategically, Myriad has made several key developments, including a collaboration with SOPHiA GENETICS to create a global liquid biopsy companion diagnostic solution and the acquisition of PATHOMIQ's AI-enabled diagnostic platform to enhance its oncology portfolio. The company also completed the transition of its laboratory operations to next-generation facilities designed to improve efficiency and reduce costs. As of December 31, 2025, Myriad employed approximately 2,700 full-time equivalent employees, with a voluntary turnover rate of 10%.
Looking ahead, Myriad Genetics aims to leverage its strategic partnerships and enhance its product offerings to drive growth in the Cancer Care Continuum, Prenatal Health, and Mental Health markets. The company is also focused on improving its operational efficiency and reducing costs as a percentage of revenue. However, it faces challenges, including potential declines in reimbursement rates and increased competition in the molecular diagnostics space. The company has indicated that it expects to continue incurring net losses in the near term as it invests in research and development and seeks to expand its market presence.
About MYRIAD GENETICS INC
Myriad Genetics, Inc. is a molecular diagnostic company specializing in precision medicine. It develops and offers genetic and genomic tests across oncology, women’s health, and pharmacogenomics to assess disease risk, guide treatment, and improve patient outcomes. Serving healthcare providers and patients, the company leverages innovative technologies, clinical evidence, and regulatory expertise to deliver actionable insights and support personalized healthcare.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.